Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Non-Current Debt (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Non-Current Debt over the past 15 years, most recently at $5.8 million for Q2 2025.

  • For Q2 2025, Non-Current Debt fell 94.25% year-over-year to $5.8 million; the TTM value through May 2025 reached $5.8 million, down 94.25%, while the annual FY2025 figure was $5.8 million, 94.25% down from the prior year.
  • Non-Current Debt for Q2 2025 was $5.8 million at Lifecore Biomedical, Inc. \De\, down from $115.7 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $164.9 million in Q2 2021 and troughed at $5.8 million in Q2 2025.
  • A 5-year average of $85.0 million and a median of $96.3 million in 2024 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 502.1% in 2024 and later tumbled 94.25% in 2025.
  • Year by year, Non-Current Debt stood at $124.2 million in 2021, then plummeted by 35.91% to $79.6 million in 2022, then plummeted by 78.8% to $16.9 million in 2023, then crashed by 49.64% to $8.5 million in 2024, then plummeted by 31.75% to $5.8 million in 2025.
  • Business Quant data shows Non-Current Debt for LFCR at $5.8 million in Q2 2025, $115.7 million in Q1 2025, and $8.5 million in Q4 2024.